{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:32:47Z","timestamp":1793223167849,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013284","name":"European Innovation Council and Small and Medium-sized Enterprises Executive Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013284","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018703","name":"HORIZON EUROPE European Innovation Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.lanepe.2026.101795","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:06:03Z","timestamp":1785477963000},"page":"101795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Long-term adherence to glucose-lowering therapy and cardiovascular risk in type 2 diabetes: a nationwide cohort study"],"prefix":"10.1016","volume":"68","author":[{"given":"Lise B.","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3806-0577","authenticated-orcid":false,"given":"Andreas","family":"Bartholdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tri-Long","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majken K.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Guasch-Ferr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2026.101795_bib1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2026.101795_bib2","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lanepe.2026.101795_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.15277\/bjd.2019.223","article-title":"Adherence to type 2 diabetes management","volume":"19","author":"Khunti","year":"2019","journal-title":"Br J Diabetes"},{"key":"10.1016\/j.lanepe.2026.101795_bib4","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.2337\/dc16-1925","article-title":"Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis","volume":"40","author":"Khunti","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lanepe.2026.101795_bib5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2026.101795_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016982","article-title":"Economic impact of medication non-adherence by disease groups: a systematic review","volume":"8","author":"Cutler","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.lanepe.2026.101795_bib7","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1111\/dom.16408","article-title":"Long-term adherence to glucose-lowering medications in adults with diabetes: a data linkage study","volume":"27","author":"Lee","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.lanepe.2026.101795_bib8","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1186\/s12913-023-10118-1","article-title":"Group-based trajectory analysis identifies varying diabetes-related cost trajectories among type 2 diabetes patients in Texas: an empirical study using commercial insurance","volume":"23","author":"Han","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.lanepe.2026.101795_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.36100","article-title":"Glucose-lowering medication classes and cardiovascular outcomes in patients with type 2 diabetes","volume":"8","author":"Neugebauer","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.lanepe.2026.101795_bib10","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jac5.1771","article-title":"Research and scholarly methods: measuring medication adherence","volume":"6","author":"Shah","year":"2023","journal-title":"J Am Coll Clin Pharm"},{"key":"10.1016\/j.lanepe.2026.101795_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/2040622321990264","article-title":"Optimal cut-off points for adherence measure among patients with type 2 diabetes in primary care clinics: a retrospective analysis","volume":"12","author":"Lim","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.lanepe.2026.101795_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2021.107931","article-title":"Non-adherence to antidiabetic and cardiovascular drugs in type 2 diabetes mellitus and its association with renal and cardiovascular outcomes: a narrative review","volume":"35","author":"Denicol\u00f2","year":"2021","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.lanepe.2026.101795_bib13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/MLR.0b013e3182984c1f","article-title":"Group-based trajectory models","volume":"51","author":"Franklin","year":"2013","journal-title":"Med Care"},{"key":"10.1016\/j.lanepe.2026.101795_bib14","first-page":"1138","article-title":"Medication adherence trajectories: a systematic literature review","volume":"26","author":"Alhazami","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.lanepe.2026.101795_bib15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2147\/CLEP.S407019","article-title":"Validation of register-based diabetes classifiers in Danish data","volume":"15","author":"Isaksen","year":"2023","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.lanepe.2026.101795_bib18","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1177\/0962280216673085","article-title":"Group-based multi-trajectory modeling","volume":"27","author":"Nagin","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.lanepe.2026.101795_bib19","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1185\/03007990903126833","article-title":"Good and poor adherence: optimal cut-point for adherence measures using administrative claims data","volume":"25","author":"Karve","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.lanepe.2026.101795_bib20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.lanepe.2026.101795_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/wics.199","article-title":"The Bayesian information criterion: background, derivation, and applications","volume":"4","author":"Neath","year":"2012","journal-title":"WIREs Computational Stats"},{"key":"10.1016\/j.lanepe.2026.101795_bib23","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Emerging Risk Factors Collaboration","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2026.101795_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2026.101795_bib25","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2026.101795_bib26","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2026.101795_bib27","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2026.101795_bib28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.lanepe.2026.101795_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.21037\/cdt-20-302","article-title":"Pathophysiology of heart failure","volume":"11","author":"Schwinger","year":"2021","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.lanepe.2026.101795_bib30","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/S0140-6736(25)00830-X","article-title":"Early-onset type 2 diabetes: the next major diabetes transition","volume":"405","author":"Luk","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2026.101795_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fphar.2013.00091","article-title":"Determinants of patient adherence: a review of systematic reviews","volume":"4","author":"Kardas","year":"2013","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.lanepe.2026.101795_bib32","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa1408214","article-title":"Glycemic control and excess mortality in type 1 diabetes","volume":"371","author":"Lind","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2026.101795_bib33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamainternmed.2025.7409","article-title":"SGLT2 inhibitors vs GLP-1 receptor agonists for kidney outcomes in individuals with type 2 diabetes","volume":"186","author":"Jensen","year":"2026","journal-title":"JAMA Intern Med"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:40:59Z","timestamp":1793220059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226002073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"alternative-id":["S2666776226002073"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101795","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term adherence to glucose-lowering therapy and cardiovascular risk in type 2 diabetes: a nationwide cohort study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101795","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101795"}}